SCHEMBL14083702

SCHEMBL14083702

COc1ccc(NC(=O)c2ccc(-c3ncccc3Cl)c(F)c2)cc1OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 5/20 0.55
▸ RAB9A P51151 5/20 0.55
▸ SMN1; SMN2 Q16637 4/20 0.55
▸ KDM4E B2RXH2 2/20 0.55
▸ KCNQ3 O43525 1/20 0.54
▸ KCNQ2 O43526 1/20 0.54
▸ POLB P06746 2/20 0.53
▸ GRM4 Q14833 3/20 0.52
▸ MAPT P10636 2/20 0.51
▸ LMNA P02545 2/20 0.50
▸ HDAC6 Q9UBN7 1/20 0.50
▸ ALDH1A1 P00352 2/20 0.49
▸ PDE4D Q08499 1/20 0.49
▸ TP53 P04637 1/20 0.49
▸ NQO2 P16083 1/20 0.48
▸ CASP3 P42574 1/20 0.48
▸ SENP7 Q9BQF6 1/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ PKM P14618 1/20 0.48
▸ KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14083662 0.94 SMN1; SMN2 (0.59) NPC1RAB9ASMN1; SMN2KDM4EKCNQ3
SCHEMBL14083708 0.92 KCNQ3 (0.53) NPC1RAB9ASMN1; SMN2KDM4EKCNQ3
SCHEMBL14083805 0.92 POLB (0.60) NPC1RAB9ASMN1; SMN2KDM4EPOLB
SCHEMBL14083709 0.90 SMN1; SMN2 (0.55) RAB9ASMN1; SMN2KDM4EKCNQ3KCNQ2
SCHEMBL14083721 0.90 TRPV1 (0.50) NPC1RAB9ASMN1; SMN2KDM4EKCNQ3
SCHEMBL14083098 0.88 SMN1; SMN2 (0.59) NPC1RAB9ASMN1; SMN2KDM4EKCNQ3
SCHEMBL14083634 0.88 RAB9A (0.53) NPC1RAB9ASMN1; SMN2KDM4EKCNQ3
SCHEMBL14083836 0.87 GRM4 (0.53) NPC1RAB9ASMN1; SMN2KCNQ3KCNQ2
SCHEMBL14083640 0.86 RAB9A (0.55) NPC1RAB9ASMN1; SMN2KCNQ3KCNQ2
SCHEMBL14083757 0.85 GRM4 (0.63) NPC1RAB9ASMN1; SMN2KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080200524-A1 Amide compounds as ion channel ligands and uses thereof KELLY MICHAEL G 2008-08-21 — — US disclosed
US-20080200524-A1 Amide compounds as ion channel ligands and uses thereof KELLY MICHAEL G 2008-08-21 — — US disclosed
US-7338950-B2 Amide compounds as ion channel ligands and uses thereof RENOVIS, INC. (US) 2008-03-04 — — US disclosed
US-7338950-B2 Amide compounds as ion channel ligands and uses thereof RENOVIS, INC. (US) 2008-03-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200524-A1 Amide compounds as ion channel ligands and uses thereof TRPV1, TRPA1, TRPV2 NPC1 1061/4885RAB9A 1914/4885SMN1; SMN2 2099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback